SSY Gets Production, Registration Nod for Two Drugs in China

MT Newswires Live06-22

SSY Group (HKG:2005) obtained production and registration approvals for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.

The approval came as the drugs passed the regulator's consistency evaluation.

Safinamide Mesylate Tablets are mainly used in adult patients with primary Parkinson's disease and symptom fluctuation, in combination with other drugs for Parkinson's.

The Procaterol Hydrochloride Inhalation Solution is used to provide relief for airflow limitation symptoms in bronchial asthma, chronic bronchitis, and emphysema.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645183049?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 14:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645183049","market":"sh","top_or_hot":-1,"title":"SSY Gets Production, Registration Nod for Two Drugs in China","media":"MT Newswires Live","content":"<html><body><p> SSY Group (HKG:2005) obtained production and registration approvals for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.</p><p>The approval came as the drugs passed the regulator's consistency evaluation.</p><p>Safinamide Mesylate Tablets are mainly used in adult patients with primary Parkinson's disease and symptom fluctuation, in combination with other drugs for Parkinson's.</p><p>The Procaterol Hydrochloride Inhalation Solution is used to provide relief for airflow limitation symptoms in bronchial asthma, chronic bronchitis, and emphysema.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Gets Production, Registration Nod for Two Drugs in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Gets Production, Registration Nod for Two Drugs in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-22 14:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> SSY Group (HKG:2005) obtained production and registration approvals for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.</p><p>The approval came as the drugs passed the regulator's consistency evaluation.</p><p>Safinamide Mesylate Tablets are mainly used in adult patients with primary Parkinson's disease and symptom fluctuation, in combination with other drugs for Parkinson's.</p><p>The Procaterol Hydrochloride Inhalation Solution is used to provide relief for airflow limitation symptoms in bronchial asthma, chronic bronchitis, and emphysema.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SSY","symbol_name":"Sunlink Health Systems Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645183049","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645183049","pubTimestamp":1782110130,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"SSY Group (HKG:2005) obtained production and registration approvals for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution from China's National Medical Products Administrati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SSY":"Sunlink Health Systems Inc","BK1191":"制药","BK4185":"保健护理机构","02005":"石四药集团","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC"},"translate_title":"SSY两种药物在中国获得生产和注册批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSY":1.5,"02005":1},"content_text":"SSY Group (HKG:2005) obtained production and registration approvals for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The approval came as the drugs passed the regulator's consistency evaluation.Safinamide Mesylate Tablets are mainly used in adult patients with primary Parkinson's disease and symptom fluctuation, in combination with other drugs for Parkinson's.The Procaterol Hydrochloride Inhalation Solution is used to provide relief for airflow limitation symptoms in bronchial asthma, chronic bronchitis, and emphysema.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645183049","isCrawlerRequest":true}